A leg stent is placed to keep a previously blocked artery open, but for some patients, the treated segment gradually narrows again over the following months. This process, called restenosis, is a recognized possibility after any peripheral stent placement rather than a sign that something went wrong with the original procedure. Understanding why it happens helps explain why ongoing surveillance is such an important part of care after stenting.
What Actually Causes Restenosis?
Restenosis after stent placement is primarily driven by a biological process called intimal hyperplasia, in which smooth muscle cells and other tissue components proliferate within the treated segment in response to the mechanical injury caused by angioplasty and stent deployment. This is the vessel's own healing response, but when it becomes excessive, the resulting tissue growth can gradually narrow the lumen inside or around the stent. Because this is a biological response to the initial procedure itself, restenosis can occur even when the stent was placed correctly and the initial result looked excellent on imaging.
How Common Is Restenosis, and Does Location Matter?
The likelihood of restenosis varies by the artery treated, the length and severity of the original lesion, and patient-specific risk factors such as diabetes and continued smoking. Segments subject to greater mechanical stress, such as the superficial femoral artery, which flexes considerably with hip and knee movement, are generally considered more prone to restenosis than less mechanically stressed vessels, which is part of why stent design and adjunctive technologies like drug-coated balloons have been developed with this segment specifically in mind.
How Is Restenosis Detected?
Stent surveillance typically relies on duplex ultrasound performed at intervals determined by the treating physician, often starting within the first six months after the procedure and continuing periodically thereafter. This imaging assesses blood flow velocity through the stented segment, since a narrowing lumen produces a detectable change in flow characteristics before a patient may even notice recurrent symptoms. Catching restenosis at this stage, before it progresses to a flow-limiting blockage or recurrent claudication, generally allows for a less complex reintervention if treatment is needed.
What Happens If Restenosis Is Found?
If surveillance imaging or recurrent symptoms indicate significant restenosis, treatment options may include repeat balloon angioplasty, use of a drug-coated balloon specifically to address the proliferative tissue response, or, in some cases, placement of an additional stent within the original one. The choice among these options depends on the extent and pattern of the restenosis, the original stent's condition, and the treating physician's assessment of the individual case.
Where Technology Fits Into Managing This Risk
Because intimal hyperplasia is the biological driver of restenosis, some interventional strategies incorporate drug-coated balloon technology, which delivers an anti-proliferative agent to the vessel wall, either at the time of initial stenting or when treating a restenotic segment. INVAMED's Extender Drug (Eluting) PTA Balloon Catheter is one such option within the company's peripheral portfolio, alongside the self-expanding Atlas Peripheral Stent System used in initial treatment. More detail on both device categories is available on the peripheral arterial disease page.
Can restenosis be prevented entirely?
No treatment can guarantee restenosis will never occur, though certain approaches, such as drug-coated balloon technology and consistent risk factor management, are intended to reduce its likelihood. Regular surveillance remains important regardless of which techniques were used during the original procedure.
Device availability and regulatory status vary by country. Please contact INVAMED or your authorized local distributor for current regulatory information applicable to your region.